Long non-coding RNA GAS5 sensitizes renal cell carcinoma to sorafenib via miR-21/SOX5 pathway
Although the use of sorafenib appears to increase the survival rate of renal cell carcinoma (RCC) patients, there is also a proportion of patients who exhibit a poor primary response to sorafenib treatment. Therefore, it is critical to elucidate the mechanisms underlying sorafenib resistance and find representative biomarkers for sorafenib treatment in RCC patients. Herein, we identified that a long noncoding RNA GAS5 was downregulated in sorafenib nonresponsive RCCs. GAS5 overexpression conferred sorafenib sensitive to nonresponsive RCC cells, whereas knockdown of GAS5 promoted responsive RCC cells resistant to sorafenib treatment in vitro and in vivo. Mechanistically, GAS5 functioned as competing endogenous RNA to repress miR-21, which controlled its down-stream target SOX5. We proposed that GAS5 was responsible for sorafenib resistance in RCC cells and GAS5 exerted its function through the miR-21/ SOX5 axis. Our findings suggested that GAS5 downregulation may be a new marker of poor response to sorafenib and GAS5 could be a potential therapeutic target for sorafenib treatment in RCC.
| Errataetall: |
RetractionIn: Cell Cycle. 2023 Mar-Mar;22(6):733. - PMID 36728914 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Cell cycle (Georgetown, Tex.) - 18(2019), 3 vom: 01. Feb., Seite 257-263 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Lei [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.03.2020 Date Revised 02.02.2023 published: Print-Electronic RetractionIn: Cell Cycle. 2023 Mar-Mar;22(6):733. - PMID 36728914 Citation Status MEDLINE |
|---|
| doi: |
10.1080/15384101.2018.1475826 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM285396110 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM285396110 | ||
| 003 | DE-627 | ||
| 005 | 20231225045344.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/15384101.2018.1475826 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0951.xml |
| 035 | |a (DE-627)NLM285396110 | ||
| 035 | |a (NLM)29895198 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Lei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long non-coding RNA GAS5 sensitizes renal cell carcinoma to sorafenib via miR-21/SOX5 pathway |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.03.2020 | ||
| 500 | |a Date Revised 02.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a RetractionIn: Cell Cycle. 2023 Mar-Mar;22(6):733. - PMID 36728914 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Although the use of sorafenib appears to increase the survival rate of renal cell carcinoma (RCC) patients, there is also a proportion of patients who exhibit a poor primary response to sorafenib treatment. Therefore, it is critical to elucidate the mechanisms underlying sorafenib resistance and find representative biomarkers for sorafenib treatment in RCC patients. Herein, we identified that a long noncoding RNA GAS5 was downregulated in sorafenib nonresponsive RCCs. GAS5 overexpression conferred sorafenib sensitive to nonresponsive RCC cells, whereas knockdown of GAS5 promoted responsive RCC cells resistant to sorafenib treatment in vitro and in vivo. Mechanistically, GAS5 functioned as competing endogenous RNA to repress miR-21, which controlled its down-stream target SOX5. We proposed that GAS5 was responsible for sorafenib resistance in RCC cells and GAS5 exerted its function through the miR-21/ SOX5 axis. Our findings suggested that GAS5 downregulation may be a new marker of poor response to sorafenib and GAS5 could be a potential therapeutic target for sorafenib treatment in RCC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Retracted Publication | |
| 650 | 4 | |a GAS5 | |
| 650 | 4 | |a RCC | |
| 650 | 4 | |a Sorafenib | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a GAS5 long non-coding RNA, human |2 NLM | |
| 650 | 7 | |a MIRN21 microRNA, human |2 NLM | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 650 | 7 | |a RNA, Long Noncoding |2 NLM | |
| 650 | 7 | |a SOX5 protein, human |2 NLM | |
| 650 | 7 | |a SOXD Transcription Factors |2 NLM | |
| 650 | 7 | |a Sorafenib |2 NLM | |
| 650 | 7 | |a 9ZOQ3TZI87 |2 NLM | |
| 700 | 1 | |a Pang, Xinlu |e verfasserin |4 aut | |
| 700 | 1 | |a Shang, Wenjin |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Hongchang |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Yonghua |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Guiwen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell cycle (Georgetown, Tex.) |d 2002 |g 18(2019), 3 vom: 01. Feb., Seite 257-263 |w (DE-627)NLM122165837 |x 1551-4005 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2019 |g number:3 |g day:01 |g month:02 |g pages:257-263 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/15384101.2018.1475826 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2019 |e 3 |b 01 |c 02 |h 257-263 | ||